Harmicine is a β-carboline alkaloid isolated and identified as a major active compound present in many plant species and marine invertebrates. This alkaloid exhibits a wide spectrum of pharmacological activities, including antispasmodic, antipyretic, and anticancer properties. This report described the antinociceptive properties of harmicine by means of chemical experimental models in order to evaluate the use for pain relief. The results demonstrating the potential analgesic properties of harmicine administered intraperitoneally were shown with the writhing test, reducing writhes around 60% (1 mg/kg), and in the formalin test, where harmicine was more effective toward neurogenic (reducing reaction time around 60%, 1 mg/kg) than inflammatory (68% reduction, 10 mg/kg) pain responses. Furthermore, these effects may operate via vanilloid receptors as revealed by the capsaicin test (41% reduction, with 3 mg/kg), as well as via peripheral glutamate receptors as shown by the glutamate test (50% reduction, with 1 mg/kg). Moreover, the opioid antagonist naloxone hydrochloride did not interfere in the antinociceptive properties of harmicine in the writhing test, revealing that this effect may not have a relationship with the opioid systems. Concluding, this report highlights harmicine as a new candidate to be used as analgesic in the future. Therefore, further studies are being undertaken in order to understand the exact mechanisms involved with the antinociceptive properties of harmicine.
Introduction
The β-Carboline type alkaloids were first isolated from Peganum harmala species (Zygophillaceae, Syrian Rue). Throughout the last two decades, numerous β-carbolines alkaloids have been isolated and identified as major active compounds presented in many plant species and marine invertebrates such as tunicates, sea squirts, and sponges. Additionally, several β-carboline alkaloids such as harman, harmine, harmaline, harmalan and other tetrahydro-β-carbolines are distributed in several different tissues and fluids from a variety of mammals (Cao et al., 2007) .
These alkaloids exhibit a wide spectrum of pharmacological activities, including antispasmodic, antipyretic, anticancer, actions on the central nervous system such as hallucinogenic properties with central inhibition of monoamine oxidase, inhibition of platelet aggregation, and immunomodulatory effects (Farouk et al., 2008) . According to Miralles et al. (2005) several β-carbolines have shown to display high affinity and selectivity for imidazole receptors I 1 , I 2 and/or I 3 . Also, such ligands as imidazole and some β-carbolines share the ability to interact with the opioid system in the CNS reducing tolerance to opioid drugs and increasing the analgesia afforded by morphine on supraspinal region in rodents.
Considering the wide spectrum of pharmacological activities attributed to the β-carboline alkaloids and their potential for interaction with the central and peripheral nervous systems, this paper describes the antinociceptive properties of harmicine using chemical-induced nociception in mice. Therefore, the aims of this paper were: i) evaluation of the antinociceptive properties of harmicine and ii) evaluation of some mechanisms of modulation that harmicine may act through. The findings of the present work were obtained evaluating the antinociceptive properties of harmicine on the writhing, formalin, glutamate, and capsaicin tests.
Materials and methods

Synthesis of (+/−)-harmicine
The synthesis of (+)-harmicine was recently described by da Silva et al. (2009) as a novel asymmetric reduction involving a supramolecular palladium catalyst. This same approach was employed in this work to Pharmacology, Biochemistry and Behavior 102 (2012) 133-138 prepare the racemic form of harmicine by using sodium borohydride as the reducing agent. According to this procedure, tryptamine was straightforwardly converted to the corresponding amide after reacting with succinic anhydride which underwent Bischler-Napieralsky cyclization after the conversion to the corresponding ethyl ester. Reduction with sodium borohydride afforded harmicine after reduction of the lactam with alane in 5 steps and 62% overall yield from tryptamine (Fig. 1) . The compound was characterized by comparison with spectral data (IR, EIMS, 1H and 13C NMR) previously reported (da Silva et al. 2009 ).
Animals
Male Swiss mice with 25-35 g body weight were kept at 25 ± 2°C in 12 h light-dark cycles (light phase started at 7:00 am) maintained (10 animals per cage) with water and food ad libitum, for at least 7 days prior to assays. Separate groups of mice were used for each analgesic test, and the animals were used only once in the experiments. Studies were carried out in accordance with the Current Guidelines for the Veterinary Care of Laboratory Animals-Joint Working Group on Veterinary Care, Finland (Voipio et al., 2008) and were performed under the consent and surveillance of the Institute of Biology Ethics Committee for Animal Research (2127-1), University of Campinas. The number of animals and the intensity of the noxious stimuli were the minimum necessary to obtain reliable data.
Drugs
All drugs were diluted in a vehicle made of 1% 
Evaluation of locomotor activity
The ambulatory behavior was assessed in an open field as described previously (Spindola, 2010) with changes on the experimental time. The apparatus consisted of a plastic box measuring 45 × 45 × 20 cm, with the floor divided into 9 equal squares (15 × 15 cm). The number of squares crossed with all paws (crossing) was counted in a 6-min session for each animal group (n= 6), and considered indicative for the quantification of the locomotor activity. For this purpose, mice were treated intraperitoneally (i.p.) with harmicine (1, 3, 10 and 30 mg/kg), pentobarbital (35 mg/kg), or vehicle 30 min beforehand.
Writhing test
The test was performed as described previously by Spindola et al. (2010) . Groups of mice (n = 6) were treated i.p with vehicle (10 ml/ kg) and harmicine using four doses 1, 3, 10, and 30 mg/kg (i.p.). Writhings were induced by an i.p. injection of 0.8% acetic acid solution (10 ml/kg), 30 min after treatment. After this injection, the numbers of writhings (abdominal constrictions) were cumulatively counted over 15 min, for nociception evaluation. Also, in order to evaluate the participation of the opioid system in the antinociceptive properties of harmicine in the same test, different groups of mice were pre-treated with naloxone hydrochloride (opioid antagonist-1 mg/kg, i.p.) or vehicle (10 ml/kg), and after 20 min they then received morphine (20 mg/kg, i.p.), harmicine (1 mg/kg, i.p.) or vehicle, 30 min prior to acetic acid injection. Data represent the average of the total writhing observed per dose concentration.
Formalin test
The formalin test was carried out as described by Woolfe and Macdonald (1944) with few changes in the protocol. Formalin-induced pain behavior is biphasic: the initial acute phase (0-5 min, neurogenic pain) is followed by a relatively short quiescent period, which is then followed by a prolonged tonic response (25-40 min, inflammatory pain). Groups of mice (n=6) were treated i.p. with: vehicle (10 ml/kg, negative control), the positive control for the neurogenic phase morphine (20 mg/ kg, determined previously), the positive control for the inflammatory phase dexamethasone (10 mg/kg, determined previously), and the dose-response of harmicine (1, 3, 10 and 30 mg/kg). After 30 min, animals were injected with 20 μl of a formalin solution (formaldehyde 1.2%, in PBS) into the plantar surface of the right hind paw. The total time spent by animal licking or biting the injected paw, an index of nociception, was recorded for the following 40 min. 
Capsaicin test
As described by our group (Spindola et al., 2010) , different groups of animals (n = 6) were treated i.p. with vehicle (10 ml/kg) and with harmicine in a dose-response manner (1, 3, 10, and 30 mg/kg). After 30 min, 40 μl of capsaicin (1.6 μg/paw prepared in PBS) was injected in the ventral surface of the right hind paw. The time that the animals spent licking the injected paw, for the first 5 min post capsaicin injection, was recorded with a chronometer and considered as indicative of nociception.
Glutamate test
This test was performed to elucidate the possible participation of peripherally glutamatergic system as described previously (Spindola et al., 2010) , with no use of positive control. Different groups of animals (n= 6) were treated i.p. with harmicine in a dose-related manner (1, 3, 10 and 30 mg/kg). 30 min after treatments, 20 μl of glutamate solution (glutamic acid in PBS) was injected in the ventral surface of the right hind paw (10 μmol/paw), and was observed individually for 15 min. The amount of time spent licking the injected paw was chronometered and considered as indicative of nociception.
Statistical analysis
All results were submitted to one way analysis of variance (ANOVA), considering as critical level p b 0.05 to evaluate significant difference between the control and treated groups, followed by Duncan's Test, using Stat Soft® software. Graphs were designed using the Origin® software.
Results
Evaluation of locomotor activity
On a preliminary set of experiments in our laboratory, animals treated with 30 mg/kg doses of harmicine did not demonstrate acute toxicity signals, therefore this dose was chosen as the highest one to be tested on antinociceptive assays. Therefore, the dose-response curves designed for the i.p. treatment with harmicine in the following assays were determined with the logarithmic scale 1, 3, 10 and 30 mg/ kg. For locomotor activity in the open-field test, the number of crossing observed for control groups was: vehicle 70.5 ± 15 (10 ml/kg, i.p.); pentobarbital *36 ± 11 (35 mg/kg, i.p.). The dose-response treatment with harmicine (1, 3, 10 and 30 mg/kg, i.p.) produced 79 ± 13; 61 ±8; 53 ± 10; and ***14 ± 3 crossing respectively. Results expressed as mean ± S.E.M. of up to 6 animals (*P b 0.05 and ***P b 0.001). These results indicated that the dose of 30 mg/kg produced either depressive central activity, or relaxant effects, leading to misinterpretation with behavioral antinociceptive experimental models.
Writhing test
The dose-response observed in Fig. 2 showed that harmicine (1, 3, 10 and 30 mg/kg, i.p.) in the writhing test produced a significantly antinociception effect reducing writhings in mice (60%, 48%, 52%, and 75%) compared to the control group (vehicle only) (**P b 0.01; ***P b 0.001).
The results presented in Fig. 3 demonstrated that harmicine (1 mg/kg, i.p.) and the opioid agonist morphine (20 mg/kg, i.p.) produced significant antinociception which was confirmed by the reduction of writhings in mice (57% and 78%), compared to the control group (vehicle only). The pre-treatment with the opioid antagonist naloxone hydrochloride (1 mg/kg, i.p.), significantly reversed the antinociception caused by morphine, however not by harmicine (69%), suggesting that this compound does not act by this system, on this test (**P b 0.01, ***P b 0.001).
Formalin test
Results presented in Fig. 4 showed that in the first phase of formalin test (0-5 min), morphine (20 mg/kg, i.p.) and harmicine (1, 3, 10 and 30 mg/kg, i.p.) produced a significantly antinociception reducing reaction time in mice, compared to the control group (45%, 60%, 75%, 78%, and 100%). Dexamethasone (10 mg/kg, i.p.) did not show activity during this phase (*Pb 0.05; **Pb 0.01; ***Pb 0.001). Results presented in Fig. 5 showed that on the second phase of formalin test (25-40 min), morphine (20 mg/kg, i.p.), dexamethasone (10 mg/kg, i.p.), and harmicine (10 and 30 mg/kg, i.p.) produced a significant antinociceptive effect, reducing reaction time of mice (59%, 53%, 68%, and 100%) compared to the control group (vehicle only, i.p.). These results demonstrated the effectiveness of harmicine better against neurogenic pain than to inflammatory pain (*Pb 0.05; ***Pb 0.001). 
Capsaicin test
In the evaluation of the peripherally vanilloid receptors, Fig. 6 showed that in the capsaicin test, harmicine (1, 3, 10 and 30 mg/kg, i.p.) produced a significant antinociception effect (*P b 0.05; ***Pb 0.001) reducing the mice reaction time around 11%, 41%, 84%, and 90% respectively, compared to the control group (vehicle only).
Glutamate test
Evaluating the possible participation of the peripheral glutamatergic system with the glutamate test (Fig. 7) , harmicine (1, 3, 10 and 30 mg/ kg, i.p.) produced a significant antinociceptive effect (*Pb 0.05; ***Pb 0.001) reducing the reaction time of the mice around 50%, 97%, 86%, and 100% respectively, compared to the control group (vehicle only).
Discussion
Among the many lead compounds identified from natural products, β-carbolines have been described with antidepressant effects related to their binding to benzodiazepine, imidazoline, serotonin, and opiate receptors as well as MAO inhibition. Antidepressants have been postulated to modulate pain through the central and peripheral nervous systems. Effects on peripheral nociceptors, descending inhibitory pain pathways, central sensitization and brain areas involved in pain and emotional processing have also been described, providing an effective option in the treatment of some pain conditions (Herraiz et al., 2007) .
Previous findings on the biological properties of the β-carboline classes permitted to explore the antinociceptive properties of harmicine, based on chemical behavioral in vivo bioassays. Results presented herein provided consistent data to support the potential use of harmicine as a future analgesic. The most relevant findings of the present work were that harmicine administered intraperitoneally (i.p.) in mice: i) produced a significantly antinociceptive effect in the writhing test; ii) did not demonstrate activity via opioid system in the writhing test. iii) demonstrated higher effectiveness to neurogenic pain, as revealed by the formalin test; iv) seemed to act peripherally via vanilloid receptors as revealed by the capsaicin test; and v) seemed to act via peripheral ionotropic and/ or metabotropic glutamate receptors, as revealed by the glutamate test.
The locomotor activity is generally believed to be a result from brain activation, which is manifested as an excitation of central neurons and an increase in cerebral metabolism (Calabresi et al., 2000) . The present study showed that i.p. treatment with harmicine had no effects on motor coordination, as reflected by open-field test, at doses providing threshold antinociceptive activity in all animal models studied. However, i.p. harmicine at the highest dose used (30 mg/kg) affected motor coordination, as a consequence of sedation, hallucination, anxiety or fear (Prut and Belzung, 2003) .
Acetic-acid induced pain (writhing test) is a screening tool for the assessment of analgesic or anti-inflammatory properties of natural or synthetic compounds. The acid acts indirectly by inducing the release of endogenous mediators, which stimulate the nociceptive neurons. Inflammatory pain transmission primarily involves peripheral polymodal receptors around small vessels which signal to the CNS via sensory afferent C-fibers entering the dorsal horn. However this chemical method has good sensitivity but poor specificity allowing misinterpretation of the results, because this is an unspecific stimulus for nociception, sensible to drugs with different mechanisms. This problem can be avoided by complementation with other nociception models, as described herein (Collier, 1968; Kumazawa, 1996) . Our results showed that harmicine did not significantly interfere with motor performance at doses that suppressed the writhing response, suggesting the potential use for pain relief.
Moreover, this work also evaluated the possible involvement of the opioidergic system in the antinociception effects of harmicine in the same model. The opioid system modulates several physiological processes, including analgesia, stress response, and neuroendocrine function. The analgesic effect is mainly due to the actions of morphine on μ opioid receptors in dorsal root ganglion and in the dorsal horn to inhibit nerve fibers that signal pain to the brain (Kieffer, 1995) . The antinociceptive effect of harmicine possibly related to opioid receptors, was evaluated by using the opioid antagonist naloxone hydrochloride prior to the treatment of animals with the compound, in order to observe partial or total reversing effects. The antinociceptive activity of harmicine was not significantly antagonized by naloxone, suggesting that opioidergic mechanisms were not involved in the expression of the antinociceptive effect of harmicine, in this assay.
Neurogenic pain is caused by the direct activation of nociceptive nerve terminals, whereas inflammatory pain is mediated by a combination of peripheral input and spinal cord sensitization. Formalin produces significant increases in spinal levels of different mediators related to both neurogenic (amino acids, kinins) and inflammatory pathways (prostaglandins, leukotrienes) (Santos et al., 2005) . Harmicine significantly reduced both phases of the formalin test demonstrating higher activity against neurogenic (phase I) than to inflammatory pain (phase II) mediation, revealed by the significant decreasing on reaction time of the mice with lower doses of the compound in the phase I. These results prompted us to explore the harmicine's peripheral antinociceptive activity via vanilloid and glutamatergic systems, since these receptors are involved in the sensitization of several pain disorders, and are considered important targets for pain control (Santos and Calixto, 1997) .
The peripherally use of capsaicin (the pungent substance of Capsicum peppers) serves as a molecular integrator of noxious chemical stimuli, releasing neuropeptides, excitatory amino acids (glutamate and aspartate), nitric oxide and pro-inflammatory mediators in the periphery, transmitting nociceptive information to the spinal cord. Harmicine significantly reduced the neurogenic nociception caused by the intraplantar injection of capsaicin in a dose-dependent manner, as in the first phase of the formalin test (neurogenic response). One important mechanism underlying these phenomena is the modulation (sensitization) of ion channels sensible to capsaicin such as the vanilloid TRPV 1 (Szallasi et al., 1993; Caterina and Julius, 2001) , indicating that, at least in part, harmicine seemed to act via vanilloid system.
Glutamate is the predominant excitatory neurotransmitter of the central and peripheral nervous system being released at various levels of the nociceptive pathways in response to inflammation or tissue injury (Yashpal et al., 2001) . Our results also showed that i.p. administration of harmicine produced a significant inhibition of the nociceptive response caused by intraplantar injection of glutamate into the mouse hindpaw, suggesting that the compound might act via glutamatergic system. In fact, the intraplantar injection of glutamate induces direct stimulation of nociceptive neurons, releasing various inflammatory and neuropeptides involved in the transmission of pain, mediated via ligand gated inotropic glutamate (iGlu) receptors and G-protein coupled metabotropic glutamate (mGlu) receptors, corroborating the effectiveness of harmicine against neurogenic pain stimuli observed in the formalin and capsaicin tests. Compounds with these actions are good candidates for treatment of neuropathic pain (Bordi and Ugolini, 1999) .
Together, all these results highlighted harmicine as a novel important candidate for clinical use on pain relief, demonstrated by the efficacy on different pain states. Further studies are being undertaken in order to better understand the harmicine antinociceptive mechanisms of action.
Conclusion
The racemic form of (+/−) harmicine demonstrated activity against chemical experimental models of pain, suggesting the potential use for different pain disorders. The present work demonstrated that harmicine administered intraperitoneally in mice: i) produces a significantly antinociceptive activity on the writhing test, and this effect does not seem to be via the opioid system; ii) demonstrate effectiveness toward neurogenic pain, possibly involved with nociceptive terminals and/or peripheral input and spinal cord sensitization, as revealed by formalin test; iii) seems to act via vanilloid systems, as revealed by capsaicin test; iv) seems to act via peripheral glutamate systems, as revealed by glutamate test.
